InVivoMAb Anti-HIV1 env/Env polyprotein Antibody (Iv0115)

Catalog No.

VVV03106

Species reactivity

Human immunodeficiency virus 1

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env, HIV1, HIV-1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q03805

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0115

Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques., PMID:40192306

Covariation of Amino Acid Substitutions in the HIV-1 Envelope Glycoprotein gp120 and the Antisense Protein ASP Associated with Coreceptor Usage., PMID:40143251

Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell-mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets., PMID:40086815

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264

Current methods for detecting and assessing HIV-1 antibody resistance., PMID:39835119

PKR Inhibitor C16 Regulates HIV-gp120 Induced Neuronal Injury and Cognitive Impairment in Vivo and in Vitro Models., PMID:39752056

In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig., PMID:39673132

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies., PMID:39489734

Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions., PMID:39343065

Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate., PMID:39283123

The evolution of envelope function during coinfection with phylogenetically distinct human immunodeficiency virus., PMID:39251948

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs., PMID:39136461

Design of Artificial C-Peptides as Potential Anti-HIV-1 Inhibitors Based on 6-HB Formation Mechanism., PMID:38910421

Discovery of a Double-Stapled Short Peptide as a Long-Acting HIV-1 Inactivator with Potential for Oral Bioavailability., PMID:38888038

Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure., PMID:38777106

Research Strategy for Short-peptide Fusion Inhibitors Based on 6-HB Core Structure against HIV-1: A Review., PMID:38551054

gp120-derived amyloidogenic peptides form amyloid fibrils that increase HIV-1 infectivity., PMID:38443447

Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates., PMID:37531955

Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques., PMID:37399208

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies., PMID:37298729

Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response., PMID:37283743

Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates., PMID:35470665

Immune escape mutations selected by neutralizing antibodies in natural HIV-1 infection can alter coreceptor usage repertoire of the transmitted/founder virus., PMID:35144109

Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer., PMID:35121758

Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines., PMID:35095862

Covalent coupling of HIV-1 glycoprotein trimers to biodegradable calcium phosphate nanoparticles via genetically encoded aldehyde-tags., PMID:34968725

Intragenic proviral elements support transcription of defective HIV-1 proviruses., PMID:34962974

Feline Leukemia Virus-B Envelope Together With its GlycoGag and Human Immunodeficiency Virus-1 Nef Mediate Resistance to Feline SERINC5., PMID:34954236

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses., PMID:34668778

Unleashing natural antibodies against HIV-1., PMID:34111390

The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate., PMID:34101626

Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering., PMID:34077734

Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody., PMID:33649208

A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls., PMID:33640794

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations., PMID:33436439

Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo., PMID:32868878

Interaction Interface of Mason-Pfizer Monkey Virus Matrix and Envelope Proteins., PMID:32796061

Engineering antibody-based molecules for HIV treatment and cure., PMID:32732551

Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis., PMID:32726944

Polyethylene Glycol 40-Modified Peptide with High Therapeutic Efficacy in Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys., PMID:32404523

Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies., PMID:32371950

Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines., PMID:32280045

Integrin α4β7 in HIV-1 infection: A critical review., PMID:32272507

Stabilized diverse HIV-1 envelope trimers for vaccine design., PMID:32241249

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors., PMID:32197300

HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir In Vitro., PMID:32161179

CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine., PMID:32057572

Sequence and Functional Variation in the HIV-1 Rev Regulatory Axis., PMID:31906839

Pregnancy favors circulating IL-21-secreting TFH -like cell recovery in ARV-treated HIV-1-infected women., PMID:31674097

Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection., PMID:31644426

Document Download

InVivoMAb Anti-HIV1 env/Env polyprotein Antibody (Iv0115).pdf